• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

AKT1 Gene Record

  • Summary
  • Interactions
  • Claims
  • AKT1 207 Druggable GenomeClinically ActionableDrug Resistance

    Alternate Names:

    207
    AKT SERINE/THREONINE KINASE 1
    AKT1
    AKT
    CWS6
    PKB
    PKB-ALPHA
    PRKBA
    RAC
    RAC-ALPHA
    164730
    391
    ENSG00000142208
    OTTHUMG00000170795
    Proto-oncogene c-Akt
    PKB alpha
    RAC-PK-alpha
    Protein kinase B alpha
    Protein kinase B
    RAC-alpha serine/threonine-protein kinase
    2
    P31749
    AKT1_HUMAN
    PA24684
    1479
    NP_001014431
    NM_001014431
    RAC-ALPHA SERINE/THREONINE-PROTEIN KINASE (EC 2.7.1.37) (RAC-PK-ALPHA) (PROTEIN KINASE B) (PKB) (C-AKT). [SOURCE:UNIPROT/SWISSPROT;ACC:P31749]
    BE0000428
    T67619

    Gene Info:

    GuideToPharmacology Gene Category ID 285
    Human Readable Name DRUGGABLE GENOME
    CancerCommons Reported Gene Name AKT
    Target Class Enzymes
    Target Subclass EC:2.7.11.1
    Uniprot Status Swiss-Prot
    Human Readable Name KINASE
    Interpro Name Serine/threonine- / dual-specificity protein kinase, catalytic domain
    Interpro Short Name Ser/Thr_dual-sp_kinase_dom
    Interpro Type Domain
    Uniprot Evidence 1: Evidence at protein level
    Interpro Acc IPR002290
    Gene Biotype PROTEIN_CODING
    GuideToPharmacology Gene Category Name Akt (Protein kinase B, PKB) family
    (27 More Sources)

    Gene Categories: Category Details

    TRANSPORTER
    KINASE
    SERINE THREONINE KINASE
    DRUG RESISTANCE
    DRUGGABLE GENOME
    CLINICALLY ACTIONABLE
    ENZYME
    TRANSCRIPTION FACTOR

    Publications:

    Blake JF et al., 2012, Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors., J Med Chem
    Saura et al., 2017, A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors., Cancer Discov
    Jang SW et al., 2007, Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death., Proc Natl Acad Sci U S A
    Lassen et al., 2014, Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma., Mol. Cancer
    Dumble et al., 2014, Discovery of novel AKT inhibitors with enhanced anti-tumor effects in combination with the MEK inhibitor., PLoS ONE
    Pachl et al., 2013, Characterization of a chemical affinity probe targeting Akt kinases., J. Proteome Res.
    Gungor et al., 2015, Dose-Finding Quantitative 18F-FDG PET Imaging Study with the Oral Pan-AKT Inhibitor GSK2141795 in Patients with Gynecologic Malignancies., J. Nucl. Med.
    Shi et al., 2014, A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition., Cancer Discov
    Vivanco et al., 2014, A kinase-independent function of AKT promotes cancer cell survival., Elife
    Kammasud et al., 2009, 5-Substituted pyrido[2,3-d]pyrimidine, an inhibitor against three receptor tyrosine kinases., Bioorg. Med. Chem. Lett.
    Xu JL et al., 2012, Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population., Asian Pac J Cancer Prev
    Sasano et al., 2015, Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary., Mol. Cancer Res.
    Ikeda M et al., 2008, Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia., Pharmacogenomics
    Ai Y et al., 2015, Synthesis of CDDO-amino acid-nitric oxide donor trihybrids as potential antitumor agents against both drug-sensitive and drug-resistant colon cancer., J Med Chem
    Mavrakis et al., 2008, Tumorigenic activity and therapeutic inhibition of Rheb GTPase., Genes Dev.
    Venkatesan et al., 2010, Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor., J. Med. Chem.
    Karelia N et al., 2010, Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells., Bioorg Med Chem Lett
    Myers et al., 2016, Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study., Gynecol. Oncol.
    Shi H et al., 2014, Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy., Cancer Discov
    Davies et al., 2015, Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors., Mol. Cancer Ther.
    Tamura et al., 2016, Safety and tolerability of AZD5363 in Japanese patients with advanced solid tumors., Cancer Chemother. Pharmacol.
    Weller et al., 2017, Durable Control of Metastatic AKT1-Mutant WHO Grade 1 Meningothelial Meningioma by the AKT Inhibitor, AZD5363., J. Natl. Cancer Inst.
    Hyman et al., 2017, AKT Inhibition in Solid Tumors With AKT1 Mutations., J. Clin. Oncol.
    Garrett et al., 2011, Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT., Invest New Drugs
    Kastrinsky DB et al., 2015, Reengineered tricyclic anti-cancer agents., Bioorg Med Chem
    Fiorino F et al., 2011, Synthesis of 1-naphtylpiperazine derivatives as serotoninergic ligands and their evaluation as antiproliferative agents., Eur J Med Chem
    Le et al., 2016, Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer., Cancer Discov
    Itoh T et al., 2008, Eupalinin A isolated from Eupatorium chinense L. induces autophagocytosis in human leukemia HL60 cells., Bioorg Med Chem
    Chen HW et al., 2011, Inhibition of TNF-α-Induced Inflammation by andrographolide via down-regulation of the PI3K/Akt signaling pathway., J Nat Prod
    Kim EJ et al., 2010, OGA inhibition by GlcNAc-selenazoline., Bioorg Med Chem
    Kaneko R et al., 2007, Survivin down-regulation plays a crucial role in 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor-induced apoptosis in cancer., J Biol Chem
    Allen et al., 2013, Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects., Sci Transl Med
    Tirosh et al., 1999, Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation., J. Biol. Chem.
    Shome D et al., 2008, Ulcerative keratitis in gastrointestinal stromal tumor patients treated with perifosine., Ophthalmology
    Hilberg et al., 2008, BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy., Cancer Res.
    Okuzumi T et al., 2009, Inhibitor hijacking of Akt activation., Nat Chem Biol
    Won et al., 2006, Small molecule-based reversible reprogramming of cellular lifespan., Nat. Chem. Biol.
    Hudkins RL et al., 2012, Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent., J Med Chem
    Hechtman et al., 2015, AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants., Mol. Cancer Res.
    Rodina A et al., 2007, Selective compounds define Hsp90 as a major inhibitor of apoptosis in small-cell lung cancer., Nat Chem Biol
    Su JL et al., 2007, Forkhead proteins are critical for bone morphogenetic protein-2 regulation and anti-tumor activity of resveratrol., J Biol Chem
    Hsieh TC et al., 2014, Biochemical and cellular evidence demonstrating AKT-1 as a binding partner for resveratrol targeting protein NQO2., PLoS One
    Charoenrungruang S et al., 2014, Gigantol, a bibenzyl from Dendrobium draconis, inhibits the migratory behavior of non-small cell lung cancer cells., J Nat Prod
    Samadi AK et al., 2010, Withaferin A, a cytotoxic steroid from Vassobia breviflora, induces apoptosis in human head and neck squamous cell carcinoma., J Nat Prod
    Van Meter et al., 2006, Cotreatment with a novel phosphoinositide analogue inhibitor and carmustine enhances chemotherapeutic efficacy by attenuating AKT activity in gliomas., Cancer
    Barve V et al., 2006, Synthesis, molecular characterization, and biological activity of novel synthetic derivatives of chromen-4-one in human cancer cells., J Med Chem
    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
  • GIGANTOL   AKT1

    Interaction Score: 1.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24844664


    Sources:
    DTC

  • EUPALININ A   AKT1

    Interaction Score: 1.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17980607


    Sources:
    DTC

  • CHEMBL1086397   AKT1

    Interaction Score: 1.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20855208


    Sources:
    DTC

  • CHEMBL480356   AKT1

    Interaction Score: 1.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19110422


    Sources:
    DTC

  • IPATASERTIB   AKT1

    Interaction Score: 1.0

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Approval Status Phase II
    Response Type predicted – sensitive
    Indication/Tumor Type triple-receptor negative breast cancer

    PMIDs:
    22934575 27872130


    Sources:
    ClearityFoundationClinicalTrial MyCancerGenomeClinicalTrial DTC JAX-CKB TdgClinicalTrial TTD MyCancerGenome GuideToPharmacology ChemblInteractions

  • ARCHEXIN   AKT1

    Interaction Score: 0.97

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Novel drug target Novel Target
    Trial Name RX-0201 ,Archexin
    combination therapy Everolimus + RX-0201

    PMIDs:
    None found


    Sources:
    JAX-CKB TdgClinicalTrial TTD DrugBank

  • CAPIVASERTIB   AKT1

    Interaction Score: 0.89

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Indication/Tumor Type ovarian cancer
    Evidence Type Actionable
    Approval Status Phase I

    PMIDs:
    26351323 26931343 28376212 28489509


    Sources:
    ClearityFoundationClinicalTrial OncoKB JAX-CKB CIViC TTD MyCancerGenome GuideToPharmacology

  • UPROSERTIB   AKT1

    Interaction Score: 0.85

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor
    Specific Action of the Ligand Inhibition

    PMIDs:
    24735930 24978597 23795919 26429956


    Sources:
    JAX-CKB GuideToPharmacology ChemblInteractions

  • CHEMBL428963   AKT1

    Interaction Score: 0.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10592235


    Sources:
    DrugBank

  • CHEMBL259833   AKT1

    Interaction Score: 0.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10592235


    Sources:
    DrugBank

  • CANTHIN-6-ONE   AKT1

    Interaction Score: 0.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CHEMBL258844   AKT1

    Interaction Score: 0.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17603540


    Sources:
    DTC

  • 5-METHOXYCANTHINONE   AKT1

    Interaction Score: 0.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PERIFOSINE   AKT1

    Interaction Score: 0.73

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name perifosine, KRX-0401
    Novel drug target Novel Target
    Indication/Tumor Type ovarian clear cell carcinoma

    PMIDs:
    18201764 25519148


    Sources:
    MyCancerGenomeClinicalTrial JAX-CKB TdgClinicalTrial DrugBank TALC

  • TRICIRIBINE   AKT1

    Interaction Score: 0.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase I
    Response Type no benefit

    PMIDs:
    20644979


    Sources:
    ClearityFoundationBiomarkers ClearityFoundationClinicalTrial JAX-CKB TdgClinicalTrial

  • AFURESERTIB   AKT1

    Interaction Score: 0.55

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor
    Specific Action of the Ligand Inhibition

    PMIDs:
    None found


    Sources:
    TTD GuideToPharmacology ChemblInteractions

  • MK-2206   AKT1

    Interaction Score: 0.51

    Interaction Types & Directionality:
    allosteric modulator
    inhibitory allosteric modulator (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Notes
    combination therapy MK2206 + Vemurafenib
    Indication/Tumor Type melanoma

    PMIDs:
    24265152 25551293


    Sources:
    ClearityFoundationBiomarkers ClearityFoundationClinicalTrial CancerCommons MyCancerGenomeClinicalTrial JAX-CKB TdgClinicalTrial TALC MyCancerGenome GuideToPharmacology ChemblInteractions

  • MIRANSERTIB   AKT1

    Interaction Score: 0.49

    Interaction Types & Directionality:
    allosteric modulator
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? True

    PMIDs:
    None found


    Sources:
    GuideToPharmacology ChemblInteractions

  • BAY-1125976   AKT1

    Interaction Score: 0.36

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • CHEMBL257158   AKT1

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20822912


    Sources:
    DTC

  • CMX-2043   AKT1

    Interaction Score: 0.36

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • ONC-201   AKT1

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type Advanced Solid Tumor
    Response Type predicted – sensitive
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    23390247


    Sources:
    JAX-CKB

  • CHEMBL23552   AKT1

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17139284 17016423


    Sources:
    DrugBank

  • TRICIRIBINE PHOSPHATE   AKT1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • SR-13668   AKT1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • MK-2201   AKT1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • MSC-2363318A   AKT1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor

    PMIDs:
    None found


    Sources:
    TTD ChemblInteractions

  • AZD-5363   AKT1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • XL-418   AKT1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction yes
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor
    Novel drug target Novel Target

    PMIDs:
    None found


    Sources:
    TdgClinicalTrial ChemblInteractions

  • GAMBOGIC AMIDE   AKT1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17911251


    Sources:
    DTC

  • CHEMBL379218   AKT1

    Interaction Score: 0.24

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? True

    PMIDs:
    None found


    Sources:
    GuideToPharmacology

  • ANDROGRAPHOLIDE   AKT1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22026410


    Sources:
    DTC

  • BARDOXOLONE METHYL   AKT1

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25675144


    Sources:
    DTC

  • LY-2780301   AKT1

    Interaction Score: 0.15

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serine/threonine-protein kinase AKT inhibitor
    Direct Interaction yes

    PMIDs:
    None found


    Sources:
    ChemblInteractions

  • A-443654   AKT1

    Interaction Score: 0.14

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Direct Interaction? True
    Endogenous Drug? False
    Specific Action of the Ligand Inhibition

    PMIDs:
    19465931


    Sources:
    DTC GuideToPharmacology

  • LY-294002   AKT1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16767085


    Sources:
    DTC

  • WITHAFERIN A   AKT1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20726569


    Sources:
    DTC

  • NELFINAVIR   AKT1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC

  • CANERTINIB   AKT1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • TOPOTECAN   AKT1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21440338


    Sources:
    DTC

  • TEMSIROLIMUS   AKT1

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase II
    Response Type predicted – sensitive

    PMIDs:
    27016228


    Sources:
    JAX-CKB

  • ENZASTAURIN   AKT1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD DrugBank

  • CEP-11981   AKT1

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22148921


    Sources:
    DTC

  • VEMURAFENIB   AKT1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type sensitive
    combination therapy MK2206 + Vemurafenib
    Evidence Type Actionable

    PMIDs:
    24265152


    Sources:
    JAX-CKB CIViC

  • NINTEDANIB   AKT1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18559524


    Sources:
    DTC

  • GSK-690693   AKT1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Specific Action of the Ligand Inhibition
    Endogenous Drug? False
    Direct Interaction? True

    PMIDs:
    None found


    Sources:
    GuideToPharmacology ChemblInteractions

  • DABRAFENIB   AKT1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24265155


    Sources:
    CIViC

  • BMS-754807   AKT1

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • EVEROLIMUS   AKT1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Evidence Type Actionable
    Approval Status Phase Ib/II
    Response Type sensitive

    PMIDs:
    None found


    Sources:
    MyCancerGenomeClinicalTrial JAX-CKB CGI

  • GEDATOLISIB   AKT1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20166697


    Sources:
    DTC

  • PICTILISIB   AKT1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type resistant

    PMIDs:
    27604488


    Sources:
    JAX-CKB

  • TRIFLUOPERAZINE   AKT1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26372073


    Sources:
    DTC

  • ALPELISIB   AKT1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type breast cancer
    Response Type resistant
    Approval Status Preclinical - Cell culture

    PMIDs:
    27604488


    Sources:
    JAX-CKB

  • RESVERATROL   AKT1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    17513867 24968355


    Sources:
    DTC DrugBank

  • WORTMANNIN   AKT1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10187855


    Sources:
    NCI

  • OMIPALISIB   AKT1

    Interaction Score: 0.04

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    None found


    Sources:
    MyCancerGenomeClinicalTrial

  • LOVASTATIN   AKT1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17472962


    Sources:
    DTC

  • CI-1040   AKT1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    TTD

  • APITOLISIB   AKT1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type endometrial cancer
    Response Type sensitive
    Approval Status Phase II

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • CETUXIMAB   AKT1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cetuximab + Irinotecan
    Indication/Tumor Type colorectal cancer
    Response Type resistant

    PMIDs:
    25714871


    Sources:
    JAX-CKB

  • IRINOTECAN   AKT1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cetuximab + Irinotecan
    Indication/Tumor Type colorectal cancer
    Response Type resistant

    PMIDs:
    25714871


    Sources:
    JAX-CKB

  • LAUROGUADINE   AKT1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ADENOSINE TRIPHOSPHATE   AKT1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17041888


    Sources:
    DrugBank

  • SIROLIMUS   AKT1

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Response Type predicted – sensitive
    combination therapy Doxorubicin + Sirolimus
    Evidence Type Actionable

    PMIDs:
    18708578


    Sources:
    JAX-CKB

  • GENISTEIN   AKT1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16789737


    Sources:
    DrugBank

  • FASUDIL   AKT1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • RISPERIDONE   AKT1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18855532


    Sources:
    PharmGKB

  • CISPLATIN   AKT1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cisplatin + Perifosine
    Indication/Tumor Type ovarian clear cell carcinoma
    Response Type predicted – sensitive

    PMIDs:
    22901187 25519148


    Sources:
    PharmGKB JAX-CKB

  • CARBOPLATIN   AKT1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22901187


    Sources:
    PharmGKB

  • GSK-269962A   AKT1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DOXORUBICIN   AKT1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type lymphoma
    Response Type decreased response
    Approval Status Preclinical - Cell line xenograft

    PMIDs:
    18708578


    Sources:
    JAX-CKB

  • SOTRASTAURIN   AKT1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • CENISERTIB   AKT1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:
    Notes

    PMIDs:
    None found


    Sources:
    TALC MyCancerGenome

  • CHEMBL225519   AKT1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • GEMCITABINE   AKT1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cisplatin + Gemcitabine + Sorafenib
    Indication/Tumor Type invasive bladder transitional cell carcinoma
    Response Type predicted – resistant

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • SORAFENIB   AKT1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Cisplatin + Gemcitabine + Sorafenib
    Indication/Tumor Type invasive bladder transitional cell carcinoma
    Response Type predicted – resistant

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • CYC-116   AKT1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • PACLITAXEL   AKT1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Ipatasertib + Paclitaxel
    Indication/Tumor Type triple-receptor negative breast cancer
    Response Type predicted – sensitive

    PMIDs:
    None found


    Sources:
    JAX-CKB

  • Ensembl: ENSG00000142208

    • Version: 101_38

    Alternate Names:
    AKT1 Ensembl Gene Name

    Gene Info:
    Gene Biotype PROTEIN_CODING

    Publications:

  • TdgClinicalTrial: P31749

    • Version: January-2014

    Alternate Names:
    AKT1 Gene Symbol

    Gene Info:
    Target Class Enzymes
    Target Subclass EC:2.7.11.1

    Publications:

  • RussLampel: ENSG00000142208

    • Version: 26-July-2011

    Alternate Names:
    RAC-ALPHA SERINE/THREONINE-PROTEIN KINASE (EC 2.7.1.37) (RAC-PK-ALPHA) (PROTEIN KINASE B) (PKB) (C-AKT). [SOURCE:UNIPROT/SWISSPROT;ACC:P31749] Description
    ENSG00000142208 Ensembl Gene Id
    AKT1 Display Id

    Gene Info:
    Human Readable Name DRUGGABLE GENOME

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • HopkinsGroom: P31749

    • Version: 11-September-2012

    Alternate Names:
    P31749 Uniprot Accession
    RAC-ALPHA SERINE/THREONINE-PROTEIN KINASE Uniprot Protein Name
    207 Entrez Gene Id

    Gene Info:
    Uniprot Status Swiss-Prot
    Human Readable Name KINASE
    Interpro Name Serine/threonine- / dual-specificity protein kinase, catalytic domain

    Gene Categories:
    KINASE, DRUGGABLE GENOME

    Publications:

  • CancerCommons: AKT1

    • Version: 25-July-2013

    Alternate Names:
    207 Entrez Gene ID

    Gene Info:
    CancerCommons Reported Gene Name AKT

    Publications:

  • GuideToPharmacology: 207

    • Version: 29-September-2020

    Alternate Names:
    391 HUGO Gene ID
    391 HUGO Gene Symbol
    AKT serine/threonine kinase 1 HUGO Gene Name

    Gene Info:
    GuideToPharmacology Gene Category Name Akt (Protein kinase B, PKB) family
    GuideToPharmacology Gene Category ID 285

    Gene Categories:
    ENZYME

    Publications:

  • JAX-CKB: AKT1

    • Version: 27-September-2017

    Alternate Names:
    207 CKB Entrez Id
    AKT1 CKB Gene Synonym
    AKT CKB Gene Synonym

    Gene Info:

    Publications:
    Shi et al., 2014, A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition., Cancer Discov
    Le et al., 2016, Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer., Cancer Discov
    Sasano et al., 2015, Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary., Mol. Cancer Res.

  • PharmGKB: AKT1

    • Version: 18-August-2020

    Alternate Names:
    PA24684 PharmGKB ID

    Gene Info:

    Publications:
    Ikeda M et al., 2008, Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia., Pharmacogenomics
    Xu JL et al., 2012, Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population., Asian Pac J Cancer Prev

  • CIViC: AKT1

    • Version: 14-September-2020

    Alternate Names:
    207 Entrez Gene ID
    2 CIViC Gene ID

    Gene Info:

    Gene Categories:
    DRUG RESISTANCE

    Publications:
    Davies et al., 2015, Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors., Mol. Cancer Ther.
    Hyman et al., 2017, AKT Inhibition in Solid Tumors With AKT1 Mutations., J. Clin. Oncol.
    Shi H et al., 2014, Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy., Cancer Discov

  • DrugBank: BE0000428

    • Version: 5.1.7

    Alternate Names:
    AKT1 DrugBank Gene Name
    P31749 UniProt Accession
    207 Entrez Gene Id

    Gene Info:

    Publications:
    Fauconneau et al., 2002, Induction of heat shock proteins (HSPs) by sodium arsenite in cultured astrocytes and reduction of hydrogen peroxide-induced cell death., J. Neurochem.
    He et al., 2003, Arsenite-induced phosphorylation of histone H3 at serine 10 is mediated by Akt1, extracellular signal-regulated kinase 2, and p90 ribosomal S6 kinase 2 but not mitogen- and stress-activated protein kinase 1., J. Biol. Chem.
    Ivanov et al., 2005, Combined treatment with EGFR inhibitors and arsenite upregulated apoptosis in human EGFR-positive melanomas: a role of suppression of the PI3K-AKT pathway., Oncogene

  • NCI: AKT1

    • Version: 14-September-2017

    Alternate Names:

    Gene Info:

    Publications:
    Tirosh et al., 1999, Oxidative stress disrupts insulin-induced cellular redistribution of insulin receptor substrate-1 and phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. A putative cellular mechanism for impaired protein kinase B activation and GLUT4 translocation., J. Biol. Chem.

  • DTC: AKT1

    • Version: 02-September-2020

    Alternate Names:

    Gene Info:

    Publications:
    Jang SW et al., 2007, Gambogic amide, a selective agonist for TrkA receptor that possesses robust neurotrophic activity, prevents neuronal cell death., Proc Natl Acad Sci U S A
    Venkatesan et al., 2010, Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor., J. Med. Chem.
    Karelia N et al., 2010, Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells., Bioorg Med Chem Lett

  • HingoraniCasas: ENSG00000142208

    • Version: 31-May-2017

    Alternate Names:
    ENSG00000142208 Gene Symbol
    AKT1 Ensembl Id

    Gene Info:

    Gene Categories:
    DRUGGABLE GENOME

    Publications:

  • MyCancerGenome: AKT1

    • Version: 20-Jun-2017

    Alternate Names:
    207 Entrez Gene Id
    AKT1 MyCancerGenome Gene Symbol
    AKT MyCancerGenome Reported Gene Name

    Gene Info:

    Publications:

  • TALC: AKT

    • Version: 12-May-2016

    Alternate Names:
    AKT Gene Symbol

    Gene Info:

    Publications:

  • ChemblInteractions: PKB

    • Version: chembl_23

    Alternate Names:
    RAC GENE_SYMBOL
    AKT1 GENE_SYMBOL
    RAC-alpha serine/threonine-protein kinase UNIPROT

    Gene Info:

    Publications:

  • OncoKB: AKT1

    • Version: 23-July-2020

    Alternate Names:
    207 OncoKB Entrez Id
    PRKBA OncoKB Gene Synonym
    RAC OncoKB Gene Synonym

    Gene Info:

    Publications:

  • HumanProteinAtlas: AKT1

    • Version: 19.3

    Alternate Names:
    ENSG00000142208 Ensembl Gene ID
    AKT Human Protein Atlas Gene Synonym
    PKB Human Protein Atlas Gene Synonym

    Gene Info:

    Gene Categories:
    ENZYME

    Publications:

  • Pharos: AKT1

    • Version: 03-September-2020

    Alternate Names:
    RAC-alpha serine/threonine-protein kinase Gene Name
    P31749 UniProt ID

    Gene Info:

    Gene Categories:
    TRANSPORTER, KINASE, TRANSCRIPTION FACTOR

    Publications:

  • GO: AKT1

    • Version: 05-September-2020

    Alternate Names:
    PKB GO Gene Synonym
    RAC GO Gene Synonym

    Gene Info:

    Gene Categories:
    KINASE, SERINE THREONINE KINASE

    Publications:

  • Tempus: AKT1

    • Version: 11-November-2018

    Alternate Names:
    AKT1 Gene Symbol

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • dGene: AKT1

    • Version: 27-Jun-2013

    Alternate Names:
    207 Gene ID
    AKT dGene Synonym
    PKB dGene Synonym

    Gene Info:

    Gene Categories:
    KINASE, SERINE THREONINE KINASE

    Publications:

  • TTD: RAC-alpha serine/threonine-protein kinase

    • Version: 2020.06.01

    Alternate Names:
    AKT1 TTD Gene Abbreviation
    T67619 TTD Target ID

    Gene Info:

    Publications:

  • CGI: AKT1

    • Version: 27-September-2017

    Alternate Names:

    Gene Info:

    Publications:

  • MskImpact: AKT1

    • Version: May-2015

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • MyCancerGenomeClinicalTrial: AKT1

    • Version: 30-February-2014

    Alternate Names:

    Gene Info:

    Publications:

  • ClearityFoundationClinicalTrial: AKT1

    • Version: 15-June-2013

    Alternate Names:

    Gene Info:

    Publications:

  • ClearityFoundationBiomarkers: AKT1

    • Version: 26-July-2013

    Alternate Names:

    Gene Info:

    Publications:

  • FoundationOneGenes: AKT1

    • Version: 03-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • CarisMolecularIntelligence: AKT1

    • Version: 04-September-2020

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

  • Oncomine: AKT1

    • Version: v3

    Alternate Names:

    Gene Info:

    Gene Categories:
    CLINICALLY ACTIONABLE

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21